Key points are not available for this paper at this time.
Background: Cognitive impairment is a common occurrence in individuals with systemic lupus erythematosus (SLE),a chronic autoimmune disease. This impairment falls under the category of centra-l nervous system disorders, known as neuropsychiatric SLE(NPSLE). The American College of Rheumatology recom-mends the use of the 1-hour neuropsychological test (ACR-NB) as the gold standard for diagnosing cognitive impairment in SLE patients. However, due to its time-consuming nature and requirement for specialized personnel, its practicality in clinical settings is limited. Therefore, the development of accurate and practical screening tools is warranted. Objectives: This study aims to evaluate the concurrent reliability and validity of Montreal Cognitive Assessment (MoCA) and Symbol Digit Modalities Test (SDMT) in identifying cognitive impairment among patients with systemic lupus erythematosus comparing with ACR-NB. Methods: Cognitive function was evaluated in 50 SLE patients and 50 healthy controls who were matched for sex, age, and years of education using ACR-NB, MoCA, and SDMT. Utilizing ACR-NB as the referencestandard, we examined three definitions of cognitive impairment, employed binary logistic regressio-n to generate predictive probabilities of combined screening tools (MoCA and SDMT), and compared the area under the curve (AUC), sensitivity, and specificity of MoCA, SDMT, and the combined screeni-ng tools. Results: As assessed by ACR-NB, the combination of MoCA and SDMT demonstrates good reliability and valid-ty, significantly reducing the required testing time.When patients were classified as severe cognitive impairment if there were two cognitive domains with SD >2 below the HC group mean,a MoCA score 1.5 below the HC group mean,the AUC value for the co-mposite screening tool was found to be 0.90 (P 2 below the HC group mean, the AUC value for the com-posite screening tool was found to be 0.85 (P Conclusion: The combined detection of MoCA and SDMT represents a quick and accurate screening tool for asses-sing cognitive impairment in patients with systemic lupus erythematosus. Acknowledgements: NIL. Disclosure of Interests: None declared.
Huang et al. (Sat,) studied this question.